Compare Apple Inc (AAPL) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs AstraZeneca plc — how do they compare? Apple Inc trades at $313.97 (market cap $4.56T), while AstraZeneca plc trades at $189.62 (market cap $294.08B). The key difference: Apple Inc is far larger — about 15.5× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.64%). Which is the better fit depends on your goals.
| AAPL | AZN | |
|---|---|---|
Market Cap | $4.56T | $294.08B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $209.48 |
52-Week Low | $202.38 | $137.44 |
Enterprise Value | $4.58T | $320.32B |
Dividend Yield | 0.35% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.03, up 0.44% today, with a bullish technical signal from moving averages and a consensus analyst price target of $329.62. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.01 surpassing the $1.95 estimate. Revenue grew to $416.16B in 2025, and net income reached $112.01B. The company maintains strong profitability with a 47.86% gross margin and 27.15% net margin, though valuation ratios like P/E of 37.61 are elevated. A dividend of $0.27 is scheduled for payment on May 14, 2026.
The outlook for AAPL remains positive driven by earnings beats and AI opportunities, but risks include high valuation, competitive pressures, and potential regulatory scrutiny. Institutional sentiment is bullish with 62.73% buy ratings, though technical indicators show mixed signals with RSI suggesting mild overbought conditions near-term.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
